Royalty Pharma Secures $250M Royalty Stream from Zymeworks' Ziihera
RPRX sits 51% above its 52-week low of $29.66.
Summary
Royalty Pharma plc has entered into a $250 million royalty funding agreement with Zymeworks Inc., a clinical-stage biopharmaceutical company. Under the terms, Royalty Pharma will receive a portion of future royalties from Zymeworks' drug Ziihera (zanidatamab-hrii), specifically 30% of worldwide tiered royalties owed by Jazz Pharmaceuticals and BeOne Medicines. This strategic investment adds a new biopharmaceutical royalty asset to Royalty Pharma's portfolio, consistent with its business model of acquiring high-value royalty streams. The deal includes a repayment cap, where Royalty Pharma will receive 1.65 times the note amount by December 31, 2033, or 1.925 times thereafter, providing a defined return on investment.
At the time of this announcement, RPRX was trading at $44.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.7B. The 52-week trading range was $29.66 to $46.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.